INTRODUCTION

In metastatic breast cancer (MBC) among patients with human epidermal growth factor receptor 2 (HER2) overexpressing disease, trastuzumab is indicated for use in combination with paclitaxel for first-line treatment, and as a single agent for those who have previously received one or more chemotherapy regimens (1). The safety and efficacy of trastuzumab in MBC have been evaluated in numerous clinical trials (2-10). Two were particularly relevant for establishing the current indication in MBC (1). One was a multicenter, randomized, open-label trial conducted in 469 women who had not been previously treated with chemotherapy for metastatic disease
. In this trial, patients were randomly assigned to receive standard chemotherapy alone (n = 234) or standard chemotherapy plus trastuzumab (n = 235). Standard chemotherapy consisted of doxorubicin (or epirubicin) (1, 4) (11) . The objectives of this study were to describe patterns of infused therapy in a cohort of older women who first received trastuzumab following diagnosis of MBC, and to identify factors associated with longer survival.
. In this trial, trastuzumab was studied as a single agent in a population with an average age of 50 years, ranging from 28 to 81 (4). The objective tumor response, as determined by an independent response evaluation committee, was 15% in the intent-to-treat group (4). Although trastuzumab for MBC has been studied extensively in clinical trials
MATERIAL AND METHODS
Data source The source of data for this study was the National Cancer Institute's (NCI) SEER cancer registry linked to Medicare enrollment and claims data (SEER-Medicare data)
. This database has been described in detail elsewhere (12) . Briefly, as of 2010, SEER collects and publishes cancer incidence and survival data from 17 population-based cancer registries throughout the United States covering approximately 26% of the US population (13 (19, 20) .
In (22 (20, 31) . 
Statistical analysis
RESULTS
Characteristics of Patients
There were 610 patients who met the study inclusion criteria (Table 1 Figure 2) (Figure 3) . 
Infused Therapy in Metastatic Breast Cancer 
Overall, 70% of the cohort received first-line trastuzumab (Table 3). The proportion of patients diagnosed with de novo Stage IV disease was similar between patients who received first-line and those who received delayed trastuzumab. Most first-line trastuzumab patients received either monotherapy (31%) or trastuzumab plus a taxane (48%) as initial therapy following MBC diagnosis. In the delayed trastuzumab group, a slightly higher proportion of patients received trastuzumab alone (35%), and a slightly lower proportion received trastuzumab plus a taxane (45%) relative to firstline trastuzumab patients. During the observation period (2000-2006), the percent of patients receiving trastuzumab alone varied from 23 (2000) to 38% (in both 2003 and 2006). Longitudinal "lasagna" plots (34) were constructed to illustrate the number of administrations of trastuzumab per month, the duration of trastuzumab, and gaps in administration (
 R. I. Griffiths et al.
Figure 2. Patterns of trastuzumab use. Each row of data represents a single patient. Each colored rectangle within each row represents one month, ordered chronologically following the beginning of trastuzumab therapy, up to a maximum of 24 months. Dark blue rectangles indicate more administrations of trastuzumab in that month; light blue rectangles indicate fewer administrations; orange rectangles indicate no administrations of trastuzumab while the patient was still observed in the data set; and clear rectangles indicate that the patient was no longer observed in the data because of death or the end of the observation period. Within each of the four figures, patients are ordered from high (top of figure) to low number of trastuzumab administrations during 48 months following the beginning of therapy, a measure of both the intensity and duration of trastuzumab therapy. MBC-Metastatic breast cancer
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Infused Therapy in Metastatic Breast Cancer  (22, 35, 36) and that we failed to account for these reasons in our analyses. Although no approach completely eliminates confounding by indication in observational studies, (36) (30) . Also, we examined cancer and noncancer mortality based on the rationale that any real benefit of cancer treatment should be observed only through cancer-specific mortality, and that differences in noncancer mortality suggest confounding by indication (22) 
